Magda Marquet

Dr. Magda Marquet joined the Alume Biosciences Board of Directors in 2020. She has built, led and commercialized multiple life science companies. She is the co-founder of AltheaDx, a commercial stage, precision medicine company with the world’s leading pharmacogenomics test for anxiety and depression, and ALMA Life Sciences, LLC, an early stage investment firm creating and growing innovative healthcare companies. Dr. Marquet co-founded Althea Technologies and, as its co-CEO with full P&L responsibility, led the company to become a leader in the field and a highly profitable, commercial company. As a result, she guided Althea to a successful acquisition by Ajinomoto, a global Japanese company and leader in amino acid technology. Prior to starting Althea Technologies, Dr. Marquet held several positions in pharmaceutical development in companies such as Vical and Amylin Pharmaceuticals.

In addition to the Board of Alume Biosciences, Dr. Marquet currently serves on the following Boards: Arcturus Therapeutics (ARCT) (Compensation Committee Chair, member of the Audit Committee). She also serves on the Board of Pfenex (PFNX) (Nomination and Governance Committee) and she serves on several private companies boards such as Senté, Micronoma and HUYA Biosciences International.

As a former founder and CEO, Dr Marquet has broad operational, fund raising expertise including venture, private equity and venture debt. She also brings expertise in M&A, global commercial development, regulatory strategies and building a winning culture of innovation and strategic growth.

Dr. Marquet holds a Ph.D in Biochemical Engineering from INSA/University of Toulouse, France. She has received numerous prestigious awards throughout her career including the 2005 Regional Ernst&Young Entrepreneur of the Year award in the Life Sciences category, the Athena Pinnacle award, the Director of the Year award (Corporate Governance) from the Corporate Directors Forum and has been inducted into the CONNECT Entrepreneur Hall of Fame.